Phase II trial of domatinostat (4SC-202) in combination with avelumab in patients with previously treated advanced mismatch repair proficient oesophagogastric and colorectal adenocarcinoma : EMERGE
Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved..
BACKGROUND: Most oesophagogastric adenocarcinomas (OGAs) and colorectal cancers (CRCs) are mismatch repair proficient (MMRp), responding poorly to immune checkpoint inhibition. We evaluated the safety and efficacy of domatinostat (histone deacetylase inhibitor) plus avelumab (anti-PD-L1 antibody) in patients with previously treated inoperable, advanced/metastatic MMRp OGA and CRC.
PATIENTS AND METHODS: Eligible patients were evaluated in a multicentre, open-label dose escalation/dose expansion phase II trial. In the escalation phase, patients received escalating doses of domatinostat [100 mg once daily (OD), 200 mg OD, 200 mg twice daily (BD)] orally for 14 days followed by continuous dosing plus avelumab 10 mg/kg administered intravenously 2-weekly (2qw) to determine the recommended phase II dose (RP2D). The trial expansion phase evaluated the best objective response rate (ORR) during 6 months by RECIST version 1.1 using a Simon two-stage optimal design with 2/9 and 1/10 responses required to proceed to stage 2 in the OGA and CRC cohorts, respectively.
RESULTS: Patients (n = 40) were registered between February 2019 and October 2021. Patients in the dose escalation phase (n = 12) were evaluated to confirm the RP2D of domatinostat 200 mg BD plus avelumab 10 mg/kg. No dose-limiting toxicities were observed. Twenty-one patients were treated at the RP2D, 19 (9 OGA and 10 CRC) were assessable for the best ORR; 2 patients with CRC did not receive combination treatment and were not assessable for the primary endpoint analysis. Six patients were evaluated in the dose escalation and expansion phases. In the OGA cohort, the best ORR was 22.2% (95% one-sided confidence interval lower bound 4.1) and the median duration of disease control was 11.3 months (range 9.9-12.7 months). No responses were observed in the CRC cohort. No treatment-related grade 3-4 adverse events were reported at the RP2D.
CONCLUSIONS: Responses in the OGA cohort met the criteria to expand to stage 2 of recruitment with an acceptable safety profile. There was insufficient signal in the CRC cohort to progress to stage 2.
TRIAL REGISTRATION: NCT03812796 (registered 23rd January 2019).
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
ESMO open - 9(2024), 4 vom: 21. März, Seite 102971 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cartwright, E [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Colorectal cancer |
|---|
| Anmerkungen: |
Date Revised 30.03.2024 published: Print-Electronic ClinicalTrials.gov: NCT03812796 Citation Status Publisher |
|---|
| doi: |
10.1016/j.esmoop.2024.102971 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370081145 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370081145 | ||
| 003 | DE-627 | ||
| 005 | 20240331001223.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240324s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.esmoop.2024.102971 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1357.xml |
| 035 | |a (DE-627)NLM370081145 | ||
| 035 | |a (NLM)38518549 | ||
| 035 | |a (PII)S2059-7029(24)00739-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cartwright, E |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Phase II trial of domatinostat (4SC-202) in combination with avelumab in patients with previously treated advanced mismatch repair proficient oesophagogastric and colorectal adenocarcinoma |b EMERGE |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 30.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT03812796 | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a BACKGROUND: Most oesophagogastric adenocarcinomas (OGAs) and colorectal cancers (CRCs) are mismatch repair proficient (MMRp), responding poorly to immune checkpoint inhibition. We evaluated the safety and efficacy of domatinostat (histone deacetylase inhibitor) plus avelumab (anti-PD-L1 antibody) in patients with previously treated inoperable, advanced/metastatic MMRp OGA and CRC | ||
| 520 | |a PATIENTS AND METHODS: Eligible patients were evaluated in a multicentre, open-label dose escalation/dose expansion phase II trial. In the escalation phase, patients received escalating doses of domatinostat [100 mg once daily (OD), 200 mg OD, 200 mg twice daily (BD)] orally for 14 days followed by continuous dosing plus avelumab 10 mg/kg administered intravenously 2-weekly (2qw) to determine the recommended phase II dose (RP2D). The trial expansion phase evaluated the best objective response rate (ORR) during 6 months by RECIST version 1.1 using a Simon two-stage optimal design with 2/9 and 1/10 responses required to proceed to stage 2 in the OGA and CRC cohorts, respectively | ||
| 520 | |a RESULTS: Patients (n = 40) were registered between February 2019 and October 2021. Patients in the dose escalation phase (n = 12) were evaluated to confirm the RP2D of domatinostat 200 mg BD plus avelumab 10 mg/kg. No dose-limiting toxicities were observed. Twenty-one patients were treated at the RP2D, 19 (9 OGA and 10 CRC) were assessable for the best ORR; 2 patients with CRC did not receive combination treatment and were not assessable for the primary endpoint analysis. Six patients were evaluated in the dose escalation and expansion phases. In the OGA cohort, the best ORR was 22.2% (95% one-sided confidence interval lower bound 4.1) and the median duration of disease control was 11.3 months (range 9.9-12.7 months). No responses were observed in the CRC cohort. No treatment-related grade 3-4 adverse events were reported at the RP2D | ||
| 520 | |a CONCLUSIONS: Responses in the OGA cohort met the criteria to expand to stage 2 of recruitment with an acceptable safety profile. There was insufficient signal in the CRC cohort to progress to stage 2 | ||
| 520 | |a TRIAL REGISTRATION: NCT03812796 (registered 23rd January 2019) | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Gastrointestinal cancer | |
| 650 | 4 | |a colorectal cancer | |
| 650 | 4 | |a immune checkpoint inhibitor | |
| 650 | 4 | |a mismatch repair | |
| 700 | 1 | |a Slater, S |e verfasserin |4 aut | |
| 700 | 1 | |a Saffery, C |e verfasserin |4 aut | |
| 700 | 1 | |a Tran, A |e verfasserin |4 aut | |
| 700 | 1 | |a Turkes, F |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, G |e verfasserin |4 aut | |
| 700 | 1 | |a Aresu, M |e verfasserin |4 aut | |
| 700 | 1 | |a Kohoutova, D |e verfasserin |4 aut | |
| 700 | 1 | |a Terlizzo, M |e verfasserin |4 aut | |
| 700 | 1 | |a Zhitkov, O |e verfasserin |4 aut | |
| 700 | 1 | |a Rana, I |e verfasserin |4 aut | |
| 700 | 1 | |a Johnston, E W |e verfasserin |4 aut | |
| 700 | 1 | |a Sanna, I |e verfasserin |4 aut | |
| 700 | 1 | |a Smyth, E |e verfasserin |4 aut | |
| 700 | 1 | |a Mansoor, W |e verfasserin |4 aut | |
| 700 | 1 | |a Fribbens, C |e verfasserin |4 aut | |
| 700 | 1 | |a Rao, S |e verfasserin |4 aut | |
| 700 | 1 | |a Chau, I |e verfasserin |4 aut | |
| 700 | 1 | |a Starling, N |e verfasserin |4 aut | |
| 700 | 1 | |a Cunningham, D |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t ESMO open |d 2016 |g 9(2024), 4 vom: 21. März, Seite 102971 |w (DE-627)NLM266189539 |x 2059-7029 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2024 |g number:4 |g day:21 |g month:03 |g pages:102971 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.esmoop.2024.102971 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2024 |e 4 |b 21 |c 03 |h 102971 | ||